EXEL - Exelixis Inc Stock Price, Fair Value and News

$44.01+0.57 (+1.31%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EXEL Price Action

Last 7 days

-0.4%

Last 30 days

15.6%

Last 90 days

17.7%

Trailing 12 Months

24.8%

EXEL RSI Chart

EXEL Valuation

Market Cap

11.8B

Price/Earnings (Trailing)

17.41

Price/Sales (Trailing)

5.16

EV/EBITDA

68.54

Price/Free Cashflow

15.13

EXEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EXEL Fundamentals

EXEL Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

10.79%

Rev. Growth (Qtr)

5.19%

EXEL Earnings

Earnings (TTM)

677.9M

Earnings Growth (Yr)

64.09%

Earnings Growth (Qtr)

4.72%

EXEL Profitability

EBT Margin

4.94%

Return on Equity

31.37%

Return on Assets

24.01%

Free Cashflow Yield

6.61%

EXEL Investor Care

Buy Backs (1Y)

6.12%

Diluted EPS (TTM)

2.37

EXEL Alerts

1 major insider buys and 4 major insider sales recently.
Big jump in Earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	2.3B	2.2B	2.3B	0
2024	1.8B	2.0B	2.1B	2.2B
2023	1.7B	1.7B	1.8B	1.8B
2022	1.5B	1.6B	1.6B	1.6B
2021	1.0B	1.2B	1.3B	1.4B
2020	979.2M	998.4M	957.8M	987.5M
2019	855.6M	909.8M	956.1M	967.8M
2018	585.3M	672.4M	745.3M	853.8M
2017	256.9M	319.7M	410.0M	452.5M
2016	43.2M	71.5M	123.8M	191.5M
2015	29.6M	31.0M	34.6M	37.2M
2014	26.6M	21.3M	22.1M	25.1M
2013	38.6M	42.7M	34.8M	31.3M
2012	272.3M	247.9M	132.9M	47.5M
2011	178.7M	163.3M	237.1M	289.6M
2010	0	0	0	185.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Exelixis Inc

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

CEO	Dr. Michael M. Morrissey Ph.D.
WEBSITE	exelixis.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	1223

Exelixis Inc Frequently Asked Questions

What is the ticker symbol for Exelixis Inc? What does EXEL stand for in stocks?

EXEL is the stock ticker symbol of Exelixis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exelixis Inc (EXEL)?

As of Wed Dec 03 2025, market cap of Exelixis Inc is 11.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXEL stock?

You can check EXEL's fair value in chart for subscribers.

Is Exelixis Inc a good stock to buy?

The fair value guage provides a quick view whether EXEL is over valued or under valued. Whether Exelixis Inc is cheap or expensive depends on the assumptions which impact Exelixis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXEL.

What is Exelixis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, EXEL's PE ratio (Price to Earnings) is 17.41 and Price to Sales (PS) ratio is 5.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exelixis Inc's stock?

In the past 10 years, Exelixis Inc has provided 0.233 (multiply by 100 for percentage) rate of return.